TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05246748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Caring Theory based Education
Description: The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: The control group received solely standard education program for one sessions in prenatal period.
Study: NCT02073617

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Real-time 3-dimensional DynaCT
Description: After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
Study: NCT04455334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: walk on tie-belt treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error-augmented concept combined physical therapy group
Description: Error-augmented concept combined physical therapy
Study: NCT03807843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V184
Description: Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile physiological saline for IM injection
Study: NCT01312129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: 500mg capsules of Sulfasalazine x 3 doses 12 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule x 3 doses 12 hours apart
Study: NCT02534480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NGP 555
Description: Gamma-secretase modulator for the treatment of Alzheimer's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NGP 555
Description: Gamma-secretase modulator for the treatment of Alzheimer's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NGP 555
Description: Gamma-secretase modulator for the treatment of Alzheimer's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NGP 555
Description: Gamma-secretase modulator for the treatment of Alzheimer's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NGP 555
Description: Gamma-secretase modulator for the treatment of Alzheimer's disease
Study: NCT00884949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week.
Study: NCT02625740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local exposition of target lesion to high intensity, low-frequency ultrasound
Description: Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
Study: NCT04455334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy group
Description: conventional physical therapy

Intervention type: OTHER
Group type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study: NCT02625740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting ballon angioplasty
Description: Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow occlusion with an angioplasty balloon
Description: Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Paclitaxel infusion
Description: Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
Study: NCT04455334

Intervention type: OTHER
Group type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study: NCT03309163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patient-controlled intravenous analgesia with Tramadol
Study: NCT02625740

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic control
Description: A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiographic control
Description: A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
Study: NCT03600129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Qadratus Lumborum Block
Description: Bilateral, ultrasound - guided Quadratus Lumborum Block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Qadratus Lumborum Block
Description: Bilateral, ultrasound - guided Quadratus Lumborum Block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 milliliters of 0.375% Ropivacaine
Description: 30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30 milliliters of 0.9% NaCl
Description: 30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
Study: NCT03309163

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: Patient-controlled intravenous analgesia with Hydromorphone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine (Epidural analgesia)
Description: Patient-controlled epidural analgesia with Ropivacaine.
Study: NCT01397929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553
Description: Intravenous administration
Study: NCT04639063

Intervention type: OTHER
Intervention: Microscopic examination using H&E stained slides
Description: Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
Study: NCT03583346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6495
Description: Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
Study: NCT00000142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
Study: NCT00787722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Infusion of participant's own stem cells
Study: NCT00000142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
Study: NCT03233750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training
Description: see description in arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Resource Management
Description: During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
Study: NCT00722371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
Study: NCT03642314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self test kit
Description: HIVST receptor will be invited to priority access to PrEP sites
Study: NCT02126332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ropivacaine and sufentanil
Description: Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.

Intervention type: OTHER
Group type: OTHER
Intervention: acetaminophen, nefopam, tramadol, opidoids
Description: Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
Study: NCT01949987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one hour
Study: NCT03754647

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
Study: NCT03119311

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video-oculography
Description: Diagnostic Method for Exotropia Using Video-oculography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: APCT
Description: alternative prism cover test
Study: NCT03860753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill capsules will look same as that of active drug.
Study: NCT01620099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extrafine treatment (Clenilexx(R) or Foster(R))
Description: Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extrafine treatment (Clenilexx(R) or Foster(R))
Description: Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
Study: NCT01033942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP
Description: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Men, Many Voices (3MV)
Description: Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Many Men, Many Voices (3MV)
Description: Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Many Men, Many Voices (3MV)
Description: Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
Study: NCT04415918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab Injection
Description: A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
Study: NCT03892733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: calorie health education knowledge and skills
Description: 45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
Study: NCT02328105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dosing: AUC = 6; on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m\^2; Days 1, 8, 15
Study: NCT02932943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT02748031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slit-lamp-adapted anterior segmental photography
Description: The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
Study: NCT02257671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive
Description: Neovletta

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral contraceptive
Description: Neovletta
Study: NCT03557996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied with a brush

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Varnish
Description: NaF will be applied with a brush
Study: NCT00555308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emergency department targeted ultrasound imaging
Description: bedside ultrasound performed by emergency physician to identify hydronephrosis
Study: NCT01086839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride 6%
Description: * one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0,9%
Description: * one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days
Study: NCT02715297

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT to the resection cavity
Description: 46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
Study: NCT02463552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
Study: NCT03161054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Study: NCT02463552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
Study: NCT03357939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX03
Description: A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
Study: NCT03989739

Intervention type: DEVICE
Intervention: Da Vinci
Study: NCT03161054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
Study: NCT02591329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mail-out hard copy materials (education plus self-regulatory strategies examples)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study: NCT02582177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candicort®
Description: Apply on the affected area and around it twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizoral®
Description: Apply on the affected area and around it twice a day
Study: NCT03161054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
Study: NCT02582177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baycuten N®
Description: Apply on the affected area and around it twice a day
Study: NCT03161054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
Study: NCT02204462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBnTP
Description: A PET imaging radiotracer
Study: NCT03819127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Pill
Study: NCT01060488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GHRH+Arg, GHRH+Arg, ITT
Description: GHRH+Arg repeatability test (2 tests) + comparison with one IT test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ITT, ITT, GHRH+Arg.
Description: IT repeatability test (2 tests) + comparison with one GHRH+Arg test